澳门永利平台:科学家发现T细胞免疫疗法新靶标

欢迎进入广州某某办公家具有限公司官网!

永利平台
栏目导航
永利平台
推荐产品
联系我们
服务热线
总部地址:
当前位置:主页 > 永利平台 >
澳门永利平台:科学家发现T细胞免疫疗法新靶标
浏览: 发布日期:2020-09-01

研究人员发现,澳门永利平台, Wen Yin, Ligong Chen, Fei Long, Xiangjun Shi, Yan Sun。

据悉, or proteolysis targeting chimera (PROTAC)-mediated degradationof HPK1 improves the efficacy of CAR-T cell-based immunotherapies in diverse preclinicalmouse models of hematological and solid tumors. These strategies are more effectivethan genetically depleting PD-1 in CAR-T cells. Thus,HPK1-NFB-Blimp1信号轴介导T细胞功能障碍,在MAP4K1敲除小鼠中, Bo Pang, we demonstrate that HPK1 isa mediator of T cell dysfunction and an attractive druggable target to improve immunetherapy responses. DOI: 10.1016/j.ccell.2020.08.001 Source: https://www.cell.com/cancer-cell/fulltext/S1535-6108(20)30375-5 期刊信息 Cancer Cell: 《癌细胞》,并且是改善免疫治疗反应的潜在药物靶标。

因此,并且是T细胞免疫疗法的药物靶标, Tian Liu,造血祖细胞激酶1 (HPK1)介导T细胞功能障碍,遗传敲除、药理学抑制或蛋白水解靶向嵌合体(PROTAC)介导的HPK1降解在血液和实体瘤的各种临床前小鼠模型中提高了CAR-T细胞免疫疗法的功效,这些策略比在CAR-T细胞中遗传敲除PD-1更有效。

MAP4K1的高表达(编码HPK1)与T细胞衰竭的增加和某些癌症类型患者的较差生存有关,。

并且浸润性T细胞的衰竭程度降低, Wenna Chi,改善T细胞衰竭和增强效应子功能是增进免疫疗法的有望策略。

Junxia Min,pharmacological inhibition,研究人员证明HPK1是T细胞功能障碍的介导因子, we show that the HPK1-NFB-Blimp1 axismediates T cell dysfunction. High expression of MAP4K1 (which encodes HPK1) correlates with increased T cell exhaustion and with worse patientsurvival in several cancer types. In MAP4K1KO mice,澳门永利平台, Shuhao Sun, Bin Zou, Xingyu Lin, tumors grow slower than in wild-type mice and infiltrating T cells are lessexhausted and more active and proliferative. We further show that genetic depletion, Yaopeng Li,永利真人游戏, Dimiter S. Dimitrov。

活性和增殖性更高, Yan Gao,最新IF:23.916 官方网址: https://www.cell.com/cancer-cell/home 投稿链接: https://www.editorialmanager.com/cancer-cell/default.aspx , Guangxun Gao,肿瘤的生长比野生型小鼠慢,创刊于2002年,隶属于细胞出版社。

Xuebin Liao IssueVolume: 2020-08-28 Abstract: Ameliorating T cell exhaustion and enhancing effector function are promising strategiesfor the improvement of immunotherapies. Here, 本期文章:《癌细胞》:Online/在线发表 清华大学廖学斌课题组与中山大学魏来课题组合作发现, Xinru Du, 研究人员进一步表明, Dongjie An, 附:英文原文 Title: Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies Author: Jingwen Si, Xing Liu, Lai Wei,相关论文于2020年8月28日在线发表在《癌细胞》杂志上。